LOGIN  |  REGISTER
Viking Therapeutics

Syra Health to Participate in Lytham Partners 2024 Investor Select Conference

January 16, 2024 | Last Trade: US$0.07 0.02 -21.11

CARMEL, Ind., Jan. 16, 2024 /PRNewswire/ -- Syra Health Corp. (NASDAQ: SYRA) ("Syra Health" or the "Company"), a healthcare technology company with a mission to improve healthcare by providing innovative services and technology solutions, announced today that it will be participating in Lytham Partners 2024 Investor Select Conference taking place virtually on February 1, 2024.

1x1 Meetings

Syra Health Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at This email address is being protected from spambots. You need JavaScript enabled to view it. or register at https://lythampartners.com/select2024invreg/

Further information on the conference is available at https://lythampartners.com/select2024.

ABOUT SYRA HEALTH CORP.

Syra Health is a healthcare technology company addressing some of healthcare's most significant challenges in areas such as behavioral and mental health, digital health, and population health, by providing innovative services and technology solutions. Syra Health's products and services are centered on prevention, improved access, and affordable care. Syra Health supplies its solutions to payers, providers, life sciences organizations, academic institutions, and the government. For more information, please visit www.syrahealth.com.

For more information, please contact:

For Media Inquiries:

Christine Drury

Communications and Marketing Director

Syra Health Corp.

463-345-5180

This email address is being protected from spambots. You need JavaScript enabled to view it.

For Investor Inquiries:

Ben Shamsian

Vice President

Lytham Partners, LLC

646-829-9701

This email address is being protected from spambots. You need JavaScript enabled to view it.

Recursion

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page